{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:07:53Z","timestamp":1785186473919,"version":"3.55.0"},"reference-count":61,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Sex Transm Infect"],"accepted":{"date-parts":[[2018,8,7]]},"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Many economic evaluations of human papillomavirus vaccination should ideally consider multiple disease outcomes, including anogenital warts, respiratory papillomatosis and non-cervical cancers (eg, anal, oropharyngeal, penile, vulvar and vaginal cancers). However, published economic evaluations largely relied on estimates from single studies or informal rapid literature reviews.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We conducted a systematic review of articles up to June 2016 to identify costs and utility estimates admissible for an economic evaluation from a single-payer healthcare provider\u2019s perspective. Meta-analyses were performed for studies that used same utility elicitation tools for similar diseases. Costs were adjusted to 2016\/2017 US$.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Sixty-one papers (35 costs; 24 utilities; 2 costs and utilities) were selected from 10 742 initial records. Cost per case ranges were US$124\u2013US$883 (anogenital warts), US$6912\u2013US$52 579 (head and neck cancers), US$12 936\u2013US$51 571 (anal cancer), US$17 524\u201334 258 (vaginal cancer), US$14 686\u2013US$28 502 (vulvar cancer) and US$9975\u2013US$27 629 (penile cancer). The total cost for 14 adult patients with recurrent respiratory papillomatosis was US$137 601 (one paper).<\/jats:p>\n<jats:p>Utility per warts episode ranged from 0.651 to 1 (12 papers, various utility elicitation methods), with pooled mean EQ-5D and EQ-VAS of 0.86 (95% CI 0.85 to 0.87) and 0.74 (95% CI 0.74 to 0.75), respectively. Fifteen papers reported utilities in head and neck cancers with range 0.29 (95% CI 0.0 to 0.76) to 0.94 (95% CI 0.3 to 1.0). Mean utility reported ranged from 0.5 (95% CI 0.4 to 0.61) to 0.65 (95% CI 0.45 to 0.75) (anal cancer), 0.59 (95% CI 0.54 to 0.64) (vaginal cancer), 0.65 (95% CI 0.60 to 0.70) (vulvar cancer) and 0.79 (95% CI 0.74 to 0.84) (penile cancer).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Differences in values reported from each paper reflect variations in cancer site, disease stages, study population, treatment modality\/setting and utility elicitation methods used. As patient management changes over time, corresponding effects on both costs and utility need to be considered to ensure health economic assumptions are up-to-date and closely reflect the case mix of patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.1136\/sextrans-2018-053606","type":"journal-article","created":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T17:40:26Z","timestamp":1537551626000},"page":"28-35","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates"],"prefix":"10.1136","volume":"95","author":[{"given":"Koh Jun","family":"Ong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1398-9017","authenticated-orcid":false,"given":"Marta","family":"Checchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Pavitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J","family":"Postma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,9,21]]},"reference":[{"key":"2024092304402201000_95.1.28.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.06.060"},{"key":"2024092304402201000_95.1.28.2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200927020-00004"},{"key":"2024092304402201000_95.1.28.3","doi-asserted-by":"publisher","DOI":"10.2165\/11599470-000000000-00000"},{"key":"2024092304402201000_95.1.28.4","unstructured":"Baylor N . October 16, 2009 Approval Letter. Cervarix. Cervarix vaccines 2009."},{"key":"2024092304402201000_95.1.28.5","unstructured":"Baylor N . June 8, 2006 Approval Letter. Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant. Vaccines, Blood Biol 2006."},{"key":"2024092304402201000_95.1.28.6","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(16)30143-7"},{"key":"2024092304402201000_95.1.28.7","unstructured":"International Agency for Research on Cancer. A Review of Human Carcinogens. Part B: Biological agents. IARC Working Group on the Evaluation of Carginogenic Risks to Humans 2012."},{"key":"2024092304402201000_95.1.28.8","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.puhe.2011.01.016","article-title":"Appraisal of the burden of genital warts from a healthcare and individual patient perspective","volume":"125","author":"Scarbrough Lefebvre","year":"2011","journal-title":"Public Health"},{"key":"2024092304402201000_95.1.28.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2015.07.002"},{"key":"2024092304402201000_95.1.28.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2007.02.006"},{"key":"2024092304402201000_95.1.28.11","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.ejca.2012.04.005","article-title":"Quality-of-life among head and neck cancer survivors at one year after treatment--a systematic review","volume":"48","author":"So","year":"2012","journal-title":"Eur J Cancer"},{"key":"2024092304402201000_95.1.28.12","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. London, United Kingdom, 2013."},{"key":"2024092304402201000_95.1.28.13","unstructured":"Organisation for Economic Co-operation and Development. Country Classification 2011. 14, 2011."},{"key":"2024092304402201000_95.1.28.14","unstructured":"Personal Social Services Research Unit. Unit costs of health & social care. Kent, United Kingdom: Personal Social Services Research Unit, 2016."},{"key":"2024092304402201000_95.1.28.15","unstructured":"Bank of England. Bank of England daily spot exchange rate against Sterling. UK: Bank of England, 2015."},{"key":"2024092304402201000_95.1.28.16","doi-asserted-by":"publisher","DOI":"10.1177\/0956462415573121"},{"key":"2024092304402201000_95.1.28.17","doi-asserted-by":"publisher","DOI":"10.1258\/ijsa.2011.011218"},{"key":"2024092304402201000_95.1.28.18","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2010.048421"},{"key":"2024092304402201000_95.1.28.19","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2011-050073"},{"key":"2024092304402201000_95.1.28.20","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e3181a74c2c"},{"key":"2024092304402201000_95.1.28.21","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X99972"},{"key":"2024092304402201000_95.1.28.22","doi-asserted-by":"publisher","DOI":"10.1258\/0956462041558168"},{"key":"2024092304402201000_95.1.28.23","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2009.040188"},{"key":"2024092304402201000_95.1.28.24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3111\/13696990801961611","article-title":"Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium","volume":"11","author":"Annemans","year":"2008","journal-title":"J Med Econ"},{"key":"2024092304402201000_95.1.28.25","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2008.030999"},{"key":"2024092304402201000_95.1.28.26","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/ijc.28145","article-title":"The burden and costs of prevention and management of genital disease caused by HPV in women: a population-based registry study in Finland","volume":"133","author":"Salo","year":"2013","journal-title":"Int J Cancer"},{"key":"2024092304402201000_95.1.28.27","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3109\/00365548.2010.541492","article-title":"The annual costs associated with human papillomavirus types 6, 11, 16, and 18 infections in Finland","volume":"43","author":"Herse","year":"2011","journal-title":"Scand J Infect Dis"},{"key":"2024092304402201000_95.1.28.28","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-8-1"},{"key":"2024092304402201000_95.1.28.29","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-1"},{"key":"2024092304402201000_95.1.28.30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049699","article-title":"Economic burden of human papillomavirus-related diseases in Italy","volume":"7","author":"Baio","year":"2012","journal-title":"PLoS One"},{"key":"2024092304402201000_95.1.28.31","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1185\/03007990802485694","article-title":"Treatment patterns and associated costs for genital warts in Italy","volume":"24","author":"Merito","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"2024092304402201000_95.1.28.32","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2008.033837"},{"key":"2024092304402201000_95.1.28.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(02)85014-7"},{"key":"2024092304402201000_95.1.28.34","doi-asserted-by":"publisher","DOI":"10.1093\/eurpub\/ckn127"},{"key":"2024092304402201000_95.1.28.35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0139062","article-title":"Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination","volume":"10","author":"\u00d6stensson","year":"2015","journal-title":"PLoS One"},{"key":"2024092304402201000_95.1.28.36","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-12-1082","article-title":"Incidence and cost of anal, penile, vaginal and vulvar cancer in Denmark","volume":"12","author":"Olsen","year":"2012","journal-title":"BMC Public Health"},{"key":"2024092304402201000_95.1.28.37","doi-asserted-by":"crossref","first-page":"5245","DOI":"10.1016\/j.vaccine.2011.05.018","article-title":"Economic burden of HPV-related cancers in France","volume":"29","author":"Borget","year":"2011","journal-title":"Vaccine"},{"key":"2024092304402201000_95.1.28.38","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-14-1123","article-title":"The cost of anal cancer in England: retrospective hospital data analysis and Markov model","volume":"14","author":"Keeping","year":"2014","journal-title":"BMC Public Health"},{"key":"2024092304402201000_95.1.28.39","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3111\/13696998.2012.759582","article-title":"Annual cost of hospitalization, inpatient rehabilitation and sick leave of anal cancer in Germany","volume":"16","author":"Heitland","year":"2013","journal-title":"J Med Econ"},{"key":"2024092304402201000_95.1.28.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.respe.2010.06.165"},{"key":"2024092304402201000_95.1.28.41","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00405-015-3495-y","article-title":"Treatments and costs for recurrent and\/or metastatic squamous cell carcinoma of the head and neck in the Netherlands","volume":"273","author":"van der Linden","year":"2016","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"2024092304402201000_95.1.28.42","first-page":"203","article-title":"Annual cost of hospitalization, inpatient rehabilitation, and sick leave for head and neck cancers in Germany","volume":"5","author":"Klussmann","year":"2013","journal-title":"Clinicoecon Outcomes Res"},{"key":"2024092304402201000_95.1.28.43","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1758-3284-3-47","article-title":"Economic burden of resected squamous cell carcinoma of the head and neck in an incident cohort of patients in the UK","volume":"3","author":"Kim","year":"2011","journal-title":"Head Neck Oncol"},{"key":"2024092304402201000_95.1.28.44","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1758-3284-2-22","article-title":"Head and neck cancers in France: an analysis of the hospital medical information system (PMSI) database","volume":"2","author":"St Guily","year":"2010","journal-title":"Head Neck Oncol"},{"key":"2024092304402201000_95.1.28.45","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/S0959-8049(01)00292-1","article-title":"The costs of head and neck oncology: primary tumours, recurrent tumours and long-term follow-up","volume":"37","author":"van Agthoven","year":"2001","journal-title":"Eur J Cancer"},{"key":"2024092304402201000_95.1.28.46","first-page":"151","article-title":"The cost of running a multidisciplinary head and neck oncology service - an audit","volume":"121","author":"Corbridge","year":"2000","journal-title":"Rev Laryngol Otol Rhinol"},{"key":"2024092304402201000_95.1.28.47","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/0266-4356(90)90004-5","article-title":"Maxillofacial surgery: the economic aspect","volume":"28","author":"Lowry","year":"1990","journal-title":"Br J Oral Maxillofac Surg"},{"key":"2024092304402201000_95.1.28.48","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00405-006-0062-6","article-title":"Compliance and efficiency before and after implementation of a clinical practice guideline for laryngeal carcinomas","volume":"263","author":"van Agthoven","year":"2006","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"2024092304402201000_95.1.28.49","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-2-8"},{"key":"2024092304402201000_95.1.28.50","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlg.0000246191.90021.5e"},{"key":"2024092304402201000_95.1.28.51","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-015-2669-2","article-title":"Penile cancer treatment costs in England","volume":"15","author":"Keeping","year":"2015","journal-title":"BMC Public Health"},{"key":"2024092304402201000_95.1.28.52","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1017\/S0022215116001201","article-title":"Economic impact of recurrent respiratory papillomas in a UK adult population","volume":"130","author":"Harrison","year":"2016","journal-title":"J Laryngol Otol"},{"key":"2024092304402201000_95.1.28.53","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.clinthera.2014.11.002","article-title":"Health utilities lost and risk factors associated with HPV-induced diseases in men and women: the HPV Italian collaborative study group","volume":"37","author":"Marcellusi","year":"2015","journal-title":"Clin Ther"},{"key":"2024092304402201000_95.1.28.54","doi-asserted-by":"publisher","DOI":"10.1177\/0956462414526706"},{"key":"2024092304402201000_95.1.28.55","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-13-1065","article-title":"Impact of human papillomavirus-related genital diseases on quality of life and psychosocial wellbeing: results of an observational, health-related quality of life study in the UK","volume":"13","author":"Dominiak-Felden","year":"2013","journal-title":"BMC Public Health"},{"key":"2024092304402201000_95.1.28.56","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e3182215512"},{"key":"2024092304402201000_95.1.28.57","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.clinthera.2011.06.012","article-title":"Time trade-off procedure for measuring health utilities loss with human papillomavirus-induced diseases: a multicenter, retrospective, observational pilot study in Italy","volume":"33","author":"Mennini","year":"2011","journal-title":"Clin Ther"},{"key":"2024092304402201000_95.1.28.58","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2009.039982"},{"key":"2024092304402201000_95.1.28.59","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e318191a55e"},{"key":"2024092304402201000_95.1.28.60","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2009.037028"},{"key":"2024092304402201000_95.1.28.61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"}],"container-title":["Sexually Transmitted Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/sextrans-2018-053606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T17:56:59Z","timestamp":1727114219000},"score":1,"resource":{"primary":{"URL":"https:\/\/sti.bmj.com\/lookup\/doi\/10.1136\/sextrans-2018-053606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,21]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,23]]},"published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1136\/sextrans-2018-053606"],"URL":"https:\/\/doi.org\/10.1136\/sextrans-2018-053606","relation":{},"ISSN":["1368-4973","1472-3263"],"issn-type":[{"value":"1368-4973","type":"print"},{"value":"1472-3263","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,21]]}}}